As Biogen preps for its closely watched aducanumab FDA filing in Alzheimer’s disease, a patent threat for the company’s top-selling medicine is causing concern for one team of analysts. In a note to clients Tuesday, Bernstein analyst Ronny Gal and his team downgraded Biogen’s stock—from outperform to market-perform—based on the belief that Mylan will win… Read More »
Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but analysts figure Amgen still holds an edge. At an appeals hearing Wednesday, judges heard arguments from Amgen and Novartis’ Sandoz unit over patents protecting big-selling Enbrel until 2029. While Sandoz’s… Read More »
After forfeiting two board seats and undertaking a strategic review, AMAG Pharmaceuticals is saying goodbye to its CEO and two of its drugs. But with another med likely being pulled from the market, AMAG’s sudden decision to cut ties with its chief executive could be akin to shifting “deck chairs on the Titanic,” one analyst said. AMAG… Read More »